San Diego Business Journal

Recent Stories

Whistleblower Laws Call for Sound, Clearly Defined Policies

A tidal wave of new lawsuits claiming retaliation against so-called whistleblowers has been hitting business owners in recent years.

By Brittany Meiling August 15, 2014 4:13 p.m. share »

So Long and Thanks for All the Health Care, Biotechnology News

(Editor’s note: This is the final column on biotechnology and health care from Meghana Keshavan, who leaves the San Diego Business Journal as of this issue to join a national online publication focused on innovation in the health care industry.)

By Meghana Keshavan June 13, 2014 3:52 p.m. share »

Pfenex Seeking $74.8M in Initial Public Offering

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering. The company is looking to raise $74.8 million as it focuses development on a growing class of drugs called biosimilars, which are projected to make a large dent in big pharma sales as patents for biologic drugs expire.

By Meghana Keshavan June 13, 2014 3:12 p.m. share »
Tease photo

Isis Pharmaceuticals Gets Multimillion-Dollar Milestone Payment

Isis Pharmaceuticals Inc. has received a large milestone payment from AstraZeneca PLC.

By Meghana Keshavan June 10, 2014 4:18 p.m. share »

Solstice Biologics Names CEO With Boston VC Pedigree

Venture capital veteran from Boston joining San Diego biotech as CEO.

By Meghana Keshavan June 9, 2014 5:10 p.m. share »

Pfenex Inc. Aims for $74.8M IPO

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars.

By Meghana Keshavan June 8, 2014 4:07 p.m. share »

Pfenex Inc. Plans $74.8 M illion IPO

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars.

By Meghana Keshavan June 6, 2014 3:52 p.m. share »

New President, CFO at Celladon Says Co. Ripe to Expand Staff

I chatted recently with Paul Cleveland, a veteran biotech finance guy who has recently been brought on as president and chief financial officer for the newly public gene therapy company Celladon Corp. Cleveland most recently was CFO of Aragon Pharmaceuticals Inc., a San Diego drugmaker sold to Johnson & Johnson last August for $1 billion.

By Meghana Keshavan June 6, 2014 3:07 p.m. share »
Tease photo

Pathway Launches Breast Cancer Test With Philanthropic Twist

San Diego’s Pathway Genomics Corp. is employing a social entrepreneurship model as it launches its new genetic test for breast cancer — entering a market made more high profile and competitive after a U.S. Supreme Court ruling last year that invalidated patents on genes.

By Meghana Keshavan June 6, 2014 2:37 p.m. share »

Covert Stepping Down as CEO of Palomar Health

Michael Covert is stepping down after more than a decade as CEO of Palomar Health, heading to Texas in August to run six Houston-area hospitals.

By Meghana Keshavan June 6, 2014 2:28 p.m. share »

More stories